Written by International Journal of Pharmacology and Clinical Sciences, 2024, 13, 4, 110-111.
Published: November 2024
Type: Drug Review
Authors: Juman Alsaab,
Author(s) affiliations:
Juman Alsaab,
Pharm D Ministry of Health, Riyadh, SAUDI ARABIA.
Abstract
Regulations: had been registered in the following countries: United
States of America (USA).
Registered Company: Astellas Pharma U.S.
General Information:
Regulatory Status: R.X.
Mechanism of Action: Works as a neurokinin 3 (NK3) receptor
antagonist that blocks neurokinin B (NKB) binding on the kisspeptin/
neurokinin B/dynorphin (KNDy) neuron to modulate neuronal activity
in the thermoregulatory center. Read More…